Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)

Maj,Ewa; Papiernik,Diana; Wietrzyk,Joanna

doi:10.3892/ijo.2016.3709

Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)

Authors:
- Ewa Maj
- Diana Papiernik
- Joanna Wietrzyk
View Affiliations

Affiliations: Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland
Published online on: September 26, 2016 https://doi.org/10.3892/ijo.2016.3709
Pages: 1773-1784
Copyright: © Maj et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The discovery of tumor angiogenesis opened a new path in fighting cancer. The approval of different antiangiogenic agents, most targeting vascular endothelial growth factor (VEGF) signaling, has either increased the effectiveness of standard chemotherapy or even replaced it by offering better patient outcomes. However, an increasing number of preclinical and clinical observations have shown that the process of angiogenesis is far from clearly understood. Apart from targeting the VEGF pathway, novel strategies aim to influence other molecular factors that are involved in tumor angiogenesis. In addition, naturally occurring compounds seem to offer additional agents for influencing angiogenesis. The first concept of antiangiogenic therapy aimed to destroy tumor vessels, while it turned out that, paradoxically, antiangiogenic drugs normalized vasculature and as a result offered an improvement in chemotherapeutic delivery. In order to design an effective treatment schedule, methods for detecting the time window of normalization and biomarkers predicting patient response are needed. The initial idea that antiangiogenic therapy would be resistance-free failed to materialize and currently we still face the obstacle of resistance to antiangiogenic therapy.

View Figures

View References

1	Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, Goldberg A, Hiatt HH, Glass J and Henshaw E: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
2	Ribatti D: History of research on tumor angiogenesis. Springer; New York, NY: 2009
3	Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar : PubMed/NCBI
4	Ferrara N: Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 29:789–791. 2009. View Article : Google Scholar : PubMed/NCBI
5	Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY and Hebbel RP: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 247:495–504. 1999. View Article : Google Scholar : PubMed/NCBI
6	Cross MJ and Claesson-Welsh L: FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 22:201–207. 2001. View Article : Google Scholar : PubMed/NCBI
7	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ and McDonald DM: Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res. 69:4527–4536. 2009. View Article : Google Scholar : PubMed/NCBI
9	Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D and Jain RK: Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 91:1071–1121. 2011. View Article : Google Scholar : PubMed/NCBI
10	Carmeliet P and Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 10:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
11	Vasudev NS and Reynolds AR: Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis. 17:471–494. 2014. View Article : Google Scholar : PubMed/NCBI
12	Jain RK: Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell. 26:605–622. 2014. View Article : Google Scholar : PubMed/NCBI
13	McIntyre A and Harris AL: Metabolic and hypoxic adaptation to anti-angiogenic therapy: A target for induced essentiality. EMBO Mol Med. 7:368–379. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, et al: Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 35(Suppl): S224–S243. 2015. View Article : Google Scholar : PubMed/NCBI
15	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
16	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
17	Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI
18	Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol. 21:1804–1809. 2010. View Article : Google Scholar : PubMed/NCBI
19	Al-Husein B, Abdalla M, Trepte M, Deremer DL and Somanath PR: Antiangiogenic therapy for cancer: An update. Pharmacotherapy. 32:1095–1111. 2012. View Article : Google Scholar : PubMed/NCBI
20	Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, et al: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol. 33:3836–3838. 2015. View Article : Google Scholar : PubMed/NCBI
21	Liu JF and Matulonis UA: Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 16:876–878. 2015. View Article : Google Scholar : PubMed/NCBI
22	Krill LS and Tewari KS: Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother. 16:675–683. 2015. View Article : Google Scholar : PubMed/NCBI
23	Crafton SM and Salani R: Beyond chemotherapy: An overview and review of targeted therapy in cervical cancer. Clin Ther. 38:449–458. 2016. View Article : Google Scholar : PubMed/NCBI
24	Wu P, Nielsen TE and Clausen MH: FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 36:422–439. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wu P, Nielsen TE and Clausen MH: Small-molecule kinase inhibitors: An analysis of FDA-approved drugs. Drug Discov Today. 21:5–10. 2016. View Article : Google Scholar
26	Ciombor KK and Berlin J: Aflibercept - a decoy VEGF receptor. Curr Oncol Rep. 16:3682014. View Article : Google Scholar
27	Aprile G, Rijavec E, Fontanella C, Rihawi K and Grossi F: Ramucirumab: Preclinical research and clinical development. Onco Targets Ther. 7:1997–2006. 2014. View Article : Google Scholar : PubMed/NCBI
28	Tiwari P: Ramucirumab: Boon or bane. J Egypt Natl Canc Inst. 28:133–140. 2016. View Article : Google Scholar : PubMed/NCBI
29	(http://www.fda.gov/). Accessed 22 Apr 2016
30	Calero R, Morchon E, Johnsen JI and Serrano R: Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis. PLoS One. 9:e956282014. View Article : Google Scholar : PubMed/NCBI
31	Maj E, Filip-Psurska B, Świtalska M, Kutner A, Wietrzyk J and Vitamin D: Vitamin D analogs potentiate the antitumor effect of imatinib mesylate in a human A549 lung tumor model. Int J Mol Sci. 16:27191–27207. 2015. View Article : Google Scholar : PubMed/NCBI
32	Legros L, Bourcier C, Jacquel A, Mahon FX, Cassuto JP, Auberger P and Pagès G: Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 104:495–501. 2004. View Article : Google Scholar : PubMed/NCBI
33	Kerbel RS, Viloria-Petit A, Klement G and Rak J: ‘Accidental’ anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer. 36:1248–1257. 2000. View Article : Google Scholar : PubMed/NCBI
34	Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 105:R15–R24. 2000. View Article : Google Scholar : PubMed/NCBI
35	Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G and Kerbel RS: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62:2731–2735. 2002.PubMed/NCBI
36	Wu H, Xin Y, Zhao J, Sun D, Li W, Hu Y and Wang S: Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother Pharmacol. 68:879–887. 2011. View Article : Google Scholar : PubMed/NCBI
37	Guo XL, Lin GJ, Zhao H, Gao Y, Qian LP, Xu SR, Fu LN, Xu Q and Wang JJ: Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell. World J Gastroenterol. 9:1995–1998. 2003. View Article : Google Scholar : PubMed/NCBI
38	Blazejczyk A, Papiernik D, Porshneva K, Sadowska J and Wietrzyk J: Endothelium and cancer metastasis: Perspectives for antimetastatic therapy. Pharmacol Rep. 67:711–718. 2015. View Article : Google Scholar : PubMed/NCBI
39	Sagar SM, Yance D and Wong RK: Natural health products that inhibit angiogenesis: A potential source for investigational new agents to treat cancer-Part 1. Curr Oncol. 13:14–26. 2006.
40	Sagar SM, Yance D and Wong RK: Natural health products that inhibit angiogenesis: A potential source for investigational new agents to treat cancer-Part 2. Curr Oncol. 13:99–107. 2006.
41	Sulaiman RS, Basavarajappa HD and Corson TW: Natural product inhibitors of ocular angiogenesis. Exp Eye Res. 129:161–171. 2014. View Article : Google Scholar : PubMed/NCBI
42	Singh M, Singh P and Shukla Y: New strategies in cancer chemoprevention by phytochemicals. Front Biosci (Elite Ed). 4:426–452. 2012. View Article : Google Scholar
43	Kang X, Jin S and Zhang Q: Antitumor and antiangiogenic activity of soy phytoestrogen on 7,12-dimethylbenz[alpha] anthracene-induced mammary tumors following ovariectomy in Sprague-Dawley rats. J Food Sci. 74:H237–H242. 2009. View Article : Google Scholar : PubMed/NCBI
44	Uifălean A, Schneider S, Ionescu C, Lalk M and Iuga CA: Soy isoflavones and breast cancer cell lines: molecular mechanisms and future perspectives. Molecules. 21:E132015. View Article : Google Scholar
45	Wietrzyk J, Opolski A, Madej J and Radzikowski C: Antitumour and antimetastatic effect of genistein alone or combined with cyclophosphamide in mice transplanted with various tumours depends on the route of tumour transplantation. In Vivo. 14:357–362. 2000.PubMed/NCBI
46	Wietrzyk J, Opolski A, Madej J and Radzikowski C: The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors. Acta Pol Pharm. 57(Suppl): 5–8. 2000.
47	Wietrzyk J, Boratynski J, Grynkiewicz G, Ryczynski A, Radzikowski C and Opolski A: Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide. Anticancer Res. 21:3893–3896. 2001.
48	Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, Han JW, Kim YM, Kim BK and Lee HY: Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: Their inhibition by resveratrol. Cancer Lett. 258:63–69. 2007. View Article : Google Scholar : PubMed/NCBI
49	Yu H, Pan C, Zhao S, Wang Z, Zhang H and Wu W: Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metal-loproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother. 62:366–372. 2008. View Article : Google Scholar
50	Ma Y, Johnson CS and Trump DL: Mechanistic insights of Vitamin D anticancer effects. Vitam Horm. 100:395–431. 2016. View Article : Google Scholar : PubMed/NCBI
51	Jäpelt RB and Jakobsen J: Vitamin D in plants: A review of occurrence, analysis, and biosynthesis. Front Plant Sci. 4:1362013. View Article : Google Scholar : PubMed/NCBI
52	Haussler MR, Jurutka PW, Mizwicki M and Norman AW: Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)₂vitamin D₃: Genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab. 25:543–559. 2011. View Article : Google Scholar : PubMed/NCBI
53	Feldman D, Krishnan AV, Swami S, Giovannucci E and Feldman BJ: The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 14:342–357. 2014. View Article : Google Scholar : PubMed/NCBI
54	Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T and Hiragun A: Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol. 178:247–250. 1990. View Article : Google Scholar : PubMed/NCBI
55	Bao BY, Yao J and Lee YF: 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 27:1883–1893. 2006. View Article : Google Scholar : PubMed/NCBI
56	Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y and Mabjeesh NJ: 1alpha,25-dihydroxyvitamin D₃ (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 6:1433–1439. 2007. View Article : Google Scholar : PubMed/NCBI
57	Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL and Johnson CS: Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 69:967–975. 2009. View Article : Google Scholar : PubMed/NCBI
58	Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N and Ishiguro S: Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer. 81:730–733. 1999. View Article : Google Scholar : PubMed/NCBI
59	Nakagawa K, Sasaki Y, Kato S, Kubodera N and Okano T: 22-Oxa-1alpha,25-dihydroxyvitamin D₃ inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. 26:1044–1054. 2005. View Article : Google Scholar : PubMed/NCBI
60	Wietrzyk J, Filip B, Milczarek M, Klopotowska D, Maciejewska M, Dabrowska K, Kurzepa A, Dzimira S, Madej J and Kutner A: The influence of 1,25-dihydroxyvitamin D₃ and 1,24-dihydroxyvitamin D₃ on αvβ₃ integrin expression in cancer cell lines. Oncol Rep. 20:941–952. 2008.PubMed/NCBI
61	Jones G, Strugnell SA and DeLuca HF: Current understanding of the molecular actions of vitamin D. Physiol Rev. 78:1193–1231. 1998.PubMed/NCBI
62	Ma Y, Trump DL and Johnson CS: Vitamin D in combination cancer treatment. J Cancer. 1:101–107. 2010. View Article : Google Scholar : PubMed/NCBI
63	Leyssens C, Verlinden L and Verstuyf A: The future of vitamin D analogs. Front Physiol. 5:1222014. View Article : Google Scholar : PubMed/NCBI
64	Milczarek M, Psurski M, Kutner A and Wietrzyk J: Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer. 13:2942013. View Article : Google Scholar : PubMed/NCBI
65	Milczarek M, Filip-Psurska B, Swiętnicki W, Kutner A and Wietrzyk J: Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep. 32:491–504. 2014.PubMed/NCBI
66	Okamoto R, Delansorne R, Wakimoto N, Doan NB, Akagi T, Shen M, Ho QH, Said JW and Koeffler HP: Inecalcitol, an analog of 1α,25(OH)₂D₃, induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer. 130:2464–2473. 2012. View Article : Google Scholar
67	Protiva P, Pendyala S, Nelson C, Augenlicht LH, Lipkin M and Holt PR: Calcium and 1,25-dihydroxyvitamin D3 modulate genes of immune and inflammatory pathways in the human colon: A human crossover trial. Am J Clin Nutr. 103:1224–1231. 2016. View Article : Google Scholar : PubMed/NCBI
68	Lappe JM, Travers-Gustafson D, Davies KM, Recker RR and Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr. 85:1586–1591. 2007.PubMed/NCBI
69	Jacot W, Firmin N, Roca L, Topart D, Gallet S, Durigova A, Mirr S, Abach L, Pouderoux S, D'Hondt V, et al: Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: A randomized phase III study. Ann Oncol. 27:1235–1241. 2016. View Article : Google Scholar : PubMed/NCBI
70	Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J and Gluud C: Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. (6): CD0074692014.PubMed/NCBI
71	Crew KD: Vitamin D: Are we ready to supplement for breast cancer prevention and treatment? ISRN Oncology. 2013:2013.Article ID 483687. View Article : Google Scholar : PubMed/NCBI
72	Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
73	Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
74	Jayson GC, Hicklin DJ and Ellis LM: Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol. 9:297–303. 2012. View Article : Google Scholar : PubMed/NCBI
75	Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
76	Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
77	Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N and Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 93:14765–14770. 1996. View Article : Google Scholar : PubMed/NCBI
78	Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CYC, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF and Davidoff AM: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 13:3942–3950. 2007. View Article : Google Scholar : PubMed/NCBI
79	Myers AL, Williams RF, Ng CY, Hartwich JE and Davidoff AM: Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg. 45:1080–1085. 2010. View Article : Google Scholar : PubMed/NCBI
80	Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, et al: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 165:35–52. 2004. View Article : Google Scholar : PubMed/NCBI
81	Zhou Q, Guo P and Gallo JM: Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 14:1540–1549. 2008. View Article : Google Scholar : PubMed/NCBI
82	Zhou Q and Gallo JM: Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol. 11:301–310. 2009. View Article : Google Scholar :
83	Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 10:145–147. 2004. View Article : Google Scholar : PubMed/NCBI
84	Shi S, Chen L and Huang G: Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature. Med Oncol. 30:6982013. View Article : Google Scholar : PubMed/NCBI
85	Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al: Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 109:17561–17566. 2012. View Article : Google Scholar : PubMed/NCBI
86	Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 116:2610–2621. 2006. View Article : Google Scholar : PubMed/NCBI
87	Griffioen AW, Mans LA, de Graaf AMA, Nowak-Sliwinska P, de Hoog CL, de Jong TAM, Vyth-Dreese FA, van Beijnum JR, Bex A and Jonasch E: Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. 18:3961–3971. 2012. View Article : Google Scholar : PubMed/NCBI
88	Wolter P, Beuselinck B, Pans S and Schöffski P: Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol. 48:621–624. 2009. View Article : Google Scholar
89	Chen DR, Lin C and Wang YF: Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triple-negative breast cancer. Exp Ther Med. 10:885–888. 2015.PubMed/NCBI
90	Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al: Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:5565–5570. 2000.PubMed/NCBI
91	Zhang L, Takara K, Yamakawa D, Kidoya H and Takakura N: Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy. Cancer Sci. 107:36–44. 2016. View Article : Google Scholar :
92	McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, Gaber MW, Calabrese C, Wu J, Nathwani AC, et al: Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 76:1537–1545. 2010. View Article : Google Scholar : PubMed/NCBI
93	Dings RPM, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH and Griffin RJ: Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 13:3395–3402. 2007. View Article : Google Scholar : PubMed/NCBI
94	Vangestel C, Van de Wiele C, Van Damme N, Staelens S, Pauwels P, Reutelingsperger CPM and Peeters M: ^99mTc-(CO)₃ His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med. 52:1786–1794. 2011. View Article : Google Scholar : PubMed/NCBI
95	Hernandez-Agudo E, Mondejar T, Soto-Montenegro ML, Megias D, Mouron S, Sanchez J, Hidalgo M, Lopez-Casas PP, Mulero F, Desco M, et al: Monitoring vascular normalization induced by antiangiogenic treatment with F-fluoromisonidazole-PET. Mol Oncol. 10:704–718. 2015. View Article : Google Scholar
96	Cao Y: Off-tumor target--beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol. 7:604–608. 2010. View Article : Google Scholar : PubMed/NCBI
97	Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, Wahlberg E, Länne T, Sun B and Cao Y: Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci USA. 110:12018–12023. 2013. View Article : Google Scholar : PubMed/NCBI
98	Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD and Chin L: Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA. 98:7481–7486. 2001. View Article : Google Scholar : PubMed/NCBI
99	Pelosof LC and Gerber DE: Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clin Proc. 85:838–854. 2010. View Article : Google Scholar : PubMed/NCBI
100	Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, Wu Y, Zhu Z, Pytowski B, Liang Y, et al: Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci USA. 105:18513–18518. 2008. View Article : Google Scholar : PubMed/NCBI
101	Cao Y: Future options of anti-angiogenic cancer therapy. Chin J Cancer. 35:212016. View Article : Google Scholar : PubMed/NCBI
102	Jain RK: Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol. 31:2205–2218. 2013. View Article : Google Scholar : PubMed/NCBI
103	Loges S, Schmidt T and Carmeliet P: Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer. 1:12–25. 2010. View Article : Google Scholar : PubMed/NCBI
104	Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603. 2008. View Article : Google Scholar : PubMed/NCBI
105	van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM, Thijssen VL and Griffioen AW: The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 67:441–461. 2015. View Article : Google Scholar : PubMed/NCBI
106	Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, et al: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 23:8136–8139. 2005. View Article : Google Scholar : PubMed/NCBI
107	Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, et al: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 28:453–459. 2010. View Article : Google Scholar :
108	Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA and Teh BT: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70:1063–1071. 2010. View Article : Google Scholar : PubMed/NCBI
109	Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 11:83–95. 2007. View Article : Google Scholar : PubMed/NCBI
110	Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM and Engebraaten O: Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res. 20:404–412. 2014. View Article : Google Scholar
111	Ebos JML, Lee CR, Christensen JG, Mutsaers AJ and Kerbel RS: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 104:17069–17074. 2007. View Article : Google Scholar : PubMed/NCBI
112	Finke J, Ko J, Rini B, Rayman P, Ireland J and Cohen P: MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 11:856–861. 2011. View Article : Google Scholar : PubMed/NCBI
113	Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP and Ferrara N: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b⁺Gr1⁺ myeloid cells. Nat Biotechnol. 25:911–920. 2007. View Article : Google Scholar : PubMed/NCBI
114	Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al: Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 450:825–831. 2007. View Article : Google Scholar : PubMed/NCBI
115	Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, et al: Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30:83–95. 2011. View Article : Google Scholar : PubMed/NCBI
116	Mantovani A, Biswas SK, Galdiero MR, Sica A and Locati M: Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 229:176–185. 2013. View Article : Google Scholar
117	Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay 0T, Naeem R, Carey VJ, Richardson AL and Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005. View Article : Google Scholar : PubMed/NCBI
118	Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J and Ferrara N: PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 15:21–34. 2009. View Article : Google Scholar
119	Gerhardt H and Betsholtz C: Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314:15–23. 2003. View Article : Google Scholar : PubMed/NCBI
120	Welti J, Loges S, Dimmeler S and Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
121	Soda Y, Myskiw C, Rommel A and Verma IM: Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl). 91:439–448. 2013. View Article : Google Scholar